Beta-blockers in diabetes with stable coronary heart disease- a cause for concern?

3 September 2019 (10:05 - 10:55)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Assistant Professor Aaqib H Malik

Catholic Medical Center, Manchester (United States of America)

6 More presentations in this session

Presentation thumbnail

Peripheral neuropathy and diastolic function are associated with adverse cardiovascular outcome in patients with type 1 diabetes mellitus: results from the thousand & 1 study

Doctor M. Jensen (Herlev, DK)

Presentation thumbnail

Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial.

Miss T. de Vries (Utrecht, NL)

Abstract Slides

Presentation thumbnail

Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment

Doctor I. Ikonomidis (Athens, GR)

Presentation thumbnail

The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

Doctor A. Mader (Feldkirch, AT)

Abstract Slides

Presentation thumbnail

Tissue sodium concentration emerged as a determinant of hypertrophic vascular remodeling in type 2 diabetes

Miss S. Jung (Erlangen, DE)

Abstract Slides

Access the full session

Session thumbnail

Diabetes and the heart

The Event

ESC Congress 2019

3 September 2019 10:05 CET

You may be interested in

Webinar

Prevention of heart failure in diabetic patients at population level

Congress Session

Diabetes, obesity, and heart failure

Webinar

Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources